Patent US2798708A successfully refreshed from Google Patents.
Patent US3404007A successfully refreshed from Google Patents.
Patent US5091190A successfully refreshed from Google Patents.
US5091190A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Delivery system for administration blood-glucose lowering drug
Assignee: Alza Corp
•
Filing: 1991-02-08
•
Granted: 1992-02-25
•
Expires: 2011-02-08
Abstract
Abstract A dosage form is disclosed comprising the antidiabetic drug glipizide for administering to a patient in need of glipizide therapy.
Inventors
- 👤 Anthony L. Kuczynski
- 👤 Atul D. Ayer
- 👤 Patrick S. Wong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 03:05
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61K31/00; A61K31/64; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/2031; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
177 words
A method for stimulating insulin secretion from the beta cells or pancreatic-islet tissue in a patient in need of insulin secretion, wherein the method comprises: (a) admitting orally into the patient a dosage form comprising: (1) a wall comprising a member selected from the group consisting of a cellulose ester, cellulose ether and cellulose ester-ether, which will defines: (2) a lumen; (3) a first composition in the compartment comprising 1 mg to 100 mg of the drug N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide for stimulating insulin secretion and a pharmaceutically acceptable carrier therefore; (4) a second composition in the compartment comprising a therapeutically acceptable hydrogel; (5) an exit passageway in the wall for delivering the first composition from the lumen; (b) imbibing fluid into the dosage form causing the first composition to provide a dispensable aqueous composition and the second composition to expand and push against the first composition, whereby the first composition is delivered from the dosage form; and, (c) stimulating insulin secretion by delivering the first composition comprising 1 mg to 100 mg of the drug to the patient.
Claim 2
Independent Claim
177 words
A method for stimulating insulin secretion from the beta cells or pancreatic-islet tissue in a patient in need of insulin secretion, wherein the method comprises: (a) admitting orally into the patient a dosage form comprising: (1) a wall comprising a member selected from the group consisting of a cellulose ester, cellulose ether and cellulose ester-ether, which will defines: (2) a lumen; (3) a first composition in the compartment comprising 1 mg to 100 mg of the drug N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide for stimulating insulin secretion and a pharmaceutically acceptable carrier therefore; (4) a second composition in the compartment comprising a therapeutically acceptable hydrogel; (5) an exit passageway in the wall for delivering the first composition from the lumen; (b) imbibing fluid into the dosage form causing the first composition to provide a dispensable aqueous composition and the second composition to expand and push against the first composition, whereby the first composition is delivered from the dosage form; and, (c) stimulating insulin secretion by delivering the first composition comprising 1 mg to 100 mg of the drug to the patient.
Claim 3
Dependent Claim
157 words
An improvement in a dosage form for administering an antidiabetic drug to a patient, wherein the dosage form comprises: (a) a wall comprising a member selected from the group consisting of a cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall defines; (b) a compartment; (c) a displacement composition in the compartment comprising a therapeutically acceptable hydrogen that absorbs fluid, expands and pushes a drug composition from the compartment; (d) an exit passageway in the wall for delivering a drug composition from the compartment; and wherein the improvement comprises: (e) a drug composition in the compartment, said drug composition comprising 1 mg to 100 mg of substantially aqueous insoluble N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide and a pharmaceutically acceptable carrier therefore, which composition when in the presence of an aqueous fluid that enters the dosage form provides a dispensable aqueous composition that delivers 1 mg to 100 mg of the antidiabetic drug to the patient.
Claim 4
Dependent Claim
157 words
An improvement in a dosage form for administering an antidiabetic drug to a patient, wherein the dosage form comprises: (a) a wall comprising a member selected from the group consisting of a cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall defines; (b) a compartment; (c) a displacement composition in the compartment comprising a therapeutically acceptable hydrogen that absorbs fluid, expands and pushes a drug composition from the compartment; (d) an exit passageway in the wall for delivering a drug composition from the compartment; and wherein the improvement comprises: (e) a drug composition in the compartment, said drug composition comprising 1 mg to 100 mg of substantially aqueous insoluble N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide and a pharmaceutically acceptable carrier therefore, which composition when in the presence of an aqueous fluid that enters the dosage form provides a dispensable aqueous composition that delivers 1 mg to 100 mg of the antidiabetic drug to the patient.
References Cited (Backward Citations)
US2799241A
Cited
US2909462A
Cited
US3845770A
Cited
US3916899A
Cited
US4088864A
Cited
US4063064A
Cited
US4016880A
Cited
US4016880B1
Cited
US4200098A
Cited
US4285987A
Cited
US4708868A
Cited
US4803076A
Cited
US4851232A
Cited
US5002772A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-24 | 1995-08-26 | 1996-02-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-24 | 1999-08-26 | 2000-02-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-24 | 2003-08-26 | 2004-02-25 | $7700.00 | Window Closed / Lapsed |